A comparison between hospital follow-up and collaborative follow-up in patients with acute heart failure.

Clinical outcome Collaborative follow-up Heart failure Post discharge follow-up Transitional care

Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
Feb 2023
Historique:
revised: 31 08 2022
received: 03 05 2022
accepted: 29 09 2022
pubmed: 15 10 2022
medline: 26 1 2023
entrez: 14 10 2022
Statut: ppublish

Résumé

There are no previous studies focusing on collaborative follow-ups between hospitals and clinics for patients discharged after acute heart failure (AHF) in Japan. The purpose of this study was to determine the status of collaboration between hospitals and clinics for patients with AHF in Japan and to compare patient characteristics and clinical outcomes using a large Japanese observational database. Of 4056 consecutive patients hospitalized for AHF in the Kyoto Congestive Heart Failure registry, we analysed 2862 patients discharged to go home, who were divided into 1674 patients (58.5%) followed up at hospitals with index hospitalization (hospital follow-up group) and 1188 (41.5%) followed up in a collaborative fashion with clinics or other general hospitals (collaborative follow-up group). The primary outcome was a composite of all-cause death or heart failure (HF) hospitalization within 1 year after discharge. Previous hospitalization for HF and length of hospital stay longer than 15 days were associated with hospital follow-up. Conversely, ≥80 years of age, hypertension, and cognitive dysfunction were associated with collaborative follow-up. The cumulative 1-year incidence of the primary outcome, all cause death, and cardiovascular death were similar between the hospital and collaborative follow-up groups (31.6% vs. 29.6%, P = 0.51, 13.1% vs, 13.9%, P = 0.35, 8.4% vs. 8.2%, P = 0.96). Even after adjusting for confounders, the difference in risk for patients in the hospital follow-up group relative to those in the collaborative follow-up group remained insignificant for the primary outcome, all-cause death, and cardiovascular death (HR: 1.11, 95% CI: 0.97-1.27, P = 0.14, HR: 1.10, 95% CI: 0.91-1.33, P = 0.33, HR: 0.96, 95% CI: 0.87-1.05, P = 0.33). The cumulative 1-year incidence of HF hospitalization was higher in the hospital follow-up group than in the collaborative follow-up group (25.5% vs. 21.3%, P = 0.02). The risk of HF hospitalization was higher in the hospital follow-up group than in the collaborative follow-up group (HR: 1.19, 95% CI: 1.01-1.39, P = 0.04). In patients hospitalized for AHF, 41.5% received collaborative follow-up after discharge. The risk of HF hospitalization was higher in the hospital follow-up group than in the collaborative follow-up, although risk of the primary outcome, all-cause death, and cardiovascular death were similar between groups.

Identifiants

pubmed: 36237154
doi: 10.1002/ehf2.14200
pmc: PMC9871700
doi:

Types de publication

Comparative Study Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

353-365

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : 18059186

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Circulation. 2022 May 3;145(18):e895-e1032
pubmed: 35363499
J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133
pubmed: 24491689
Curr Heart Fail Rep. 2015 Oct;12(5):309-17
pubmed: 26289741
Ann Intern Med. 2014 Jun 3;160(11):774-84
pubmed: 24862840
ESC Heart Fail. 2017 Aug;4(3):216-223
pubmed: 28772047
Circ J. 2018 Oct 25;82(11):2811-2819
pubmed: 30259898
Am Heart J. 2003 Feb;145(2):300-9
pubmed: 12595848
BMC Fam Pract. 2020 Jan 13;21(1):8
pubmed: 31931728
JAMA Netw Open. 2019 Jun 5;2(6):e195892
pubmed: 31225889
Eur J Heart Fail. 2000 Mar;2(1):113-5
pubmed: 10742711
J Am Med Dir Assoc. 2021 Mar;22(3):621-629
pubmed: 33158744
JAMA. 2021 Jul 27;326(4):314-323
pubmed: 34313687
BMC Fam Pract. 2019 Oct 29;20(1):147
pubmed: 31664903
Circulation. 2021 May 18;143(20):1929-1931
pubmed: 34085868
Healthcare (Basel). 2020 Oct 30;8(4):
pubmed: 33143049
Circ J. 2021 Aug 25;85(9):1565-1574
pubmed: 34234052
JACC Heart Fail. 2015 Jul;3(7):542-550
pubmed: 26160370
J Am Heart Assoc. 2018 Sep 18;7(18):e008687
pubmed: 30371201
ESC Heart Fail. 2023 Feb;10(1):353-365
pubmed: 36237154
BMJ Open. 2020 Feb 16;10(2):e032674
pubmed: 32066601
CMAJ. 2005 Jan 18;172(2):189-94
pubmed: 15655239
Arch Intern Med. 2007 Jul 23;167(14):1493-502
pubmed: 17646603
JAMA. 2007 Jan 3;297(1):61-70
pubmed: 17200476
Geriatr Gerontol Int. 2015 Jun;15(6):673-87
pubmed: 25656311
ESC Heart Fail. 2021 Apr;8(2):802-818
pubmed: 33405392
JAMA. 2017 Jul 18;318(3):270-278
pubmed: 28719692
N Engl J Med. 1995 Nov 2;333(18):1190-5
pubmed: 7565975
Circ Heart Fail. 2015 Mar;8(2):384-409
pubmed: 25604605
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992

Auteurs

Koichi Washida (K)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Takao Kato (T)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Neiko Ozasa (N)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Takeshi Morimoto (T)

Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.

Hidenori Yaku (H)

Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.

Yasutaka Inuzuka (Y)

Cardiovascular Medicine, Shiga General Hospital, Moriyama, Japan.

Yodo Tamaki (Y)

Division of Cardiology, Tenri Hospital, Nara, Japan.

Yuta Seko (Y)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Erika Yamamoto (E)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Yusuke Yoshikawa (Y)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Masayuki Shiba (M)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Takeshi Kitai (T)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Yugo Yamashita (Y)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Ryoji Taniguchi (R)

Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.

Moritake Iguchi (M)

Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Kazuya Nagao (K)

Department of Cardiology, Osaka Red Cross Hospital, Osaka, Japan.

Yuichi Kawase (Y)

Department of Cardiology, Kurashiki Central Hospital, Okayama, Japan.

Yuji Nishimoto (Y)

Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.

Takashi Kuragaichi (T)

Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.

Kozo Hotta (K)

Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.

Takashi Morinaga (T)

Department of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan.

Mamoru Toyofuku (M)

Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Yutaka Furukawa (Y)

Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.

Kenji Ando (K)

Department of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan.

Kazushige Kadota (K)

Department of Cardiology, Kurashiki Central Hospital, Okayama, Japan.

Yukihito Sato (Y)

Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.

Koichiro Kuwahara (K)

Department of Cardiovascular Medicine, Shinshu University Graduate School of Medicine, Nagano, Japan.

Takeshi Kimura (T)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH